Search Videos by Topic or Participant
Browse by Series:

Potential New Biomarkers in Lung Cancer

Panelists: D. Ross Camidge, MD, PhD, University of Colorado;Ramaswamy Govindan, MD, Siteman; Roy S. Herbst, MD, PhD, Yale; Corey J. Langer, MD, Penn
Published: Wednesday, Dec 03, 2014
For High-Definition, Click
Earlier studies have suggested that patients with rich expression of EGFR might benefit from treatment with an EGFR-targeted monoclonal antibody, such as necitumumab. Researchers are currently exploring EGFR expression in tissues samples from patients enrolled in the phase III SQUIRE trial, which examined necitumumab in non-small cell lung cancer (NSCLC).

Additionally, there is interest in CDKN2A deletions as a potential predictor of response to CDK4/6 inhibitors. In a phase II study, treatment with palbociclib was well tolerated and demonstrated stable disease in 50% of evaluable patients in previously treated patients with CDKN2A inactivated NSCLC. These results warrant further investigation, believes Ramaswamy Govindan, MD.
Slider Left
Slider Right
For High-Definition, Click
Earlier studies have suggested that patients with rich expression of EGFR might benefit from treatment with an EGFR-targeted monoclonal antibody, such as necitumumab. Researchers are currently exploring EGFR expression in tissues samples from patients enrolled in the phase III SQUIRE trial, which examined necitumumab in non-small cell lung cancer (NSCLC).

Additionally, there is interest in CDKN2A deletions as a potential predictor of response to CDK4/6 inhibitors. In a phase II study, treatment with palbociclib was well tolerated and demonstrated stable disease in 50% of evaluable patients in previously treated patients with CDKN2A inactivated NSCLC. These results warrant further investigation, believes Ramaswamy Govindan, MD.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x